A new blood thinner called prasugrel has just been approved by European Union regulators.
The drug will be launched in Europe in the coming weeks under the brand name Efient, Eli Lilly & Co. spokeswoman Carole Copland told the Associated Press.
Prasugrel is designed to prevent blood clots in heart disease patients who've have stents implanted to keep their arteries open.
Earlier this month, an FDA advisory panel recommended that the agency approve prasugrel, the AP reported. The FDA has twice delayed making a decision on the drug but usually follows the advice of its advisory panels.